Aberrant arachidonic acid metabolism in esophageal adenocarcinogenesis, and the effects of sulindac, nordihydroguaiaretic acid, and α-difluoromethylornithine on tumorigenesis in a rat surgical model

Carcinogenesis

Volumn 23, Issue 12, 2002, Pages 2095-2102

  Chen, Xiaoxin ^a   Li, Ning ^a   Wang, Su ^a   Hong, Jungil ^a   Fang, Mingzhu ^a   Yousselfson, Joseph ^a   Yang, Peiying ^b   Newman, Robert A ^b   Lubet, Ronald A ^c   Yang, Chung S ^a  

^a RUTGERS UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

12 HYDROXYICOSATETRAENOIC ACID; 15 HYDROXYICOSATETRAENOIC ACID; 5 HYDROXYICOSATETRAENOIC ACID; CYCLOOXYGENASE 2; EDETIC ACID; EFLORNITHINE; ICOSANOID; IRON DEXTRAN; LEUKOTRIENE B4; NORDIHYDROGUAIARETIC ACID; PROSTAGLANDIN E2; SULINDAC;

ADENOCARCINOMA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARACHIDONIC ACID METABOLISM; BASEMENT MEMBRANE; CANCER INCIDENCE; CANCER INHIBITION; CARCINOGENESIS; CHEMOPROPHYLAXIS; COLUMNAR EPITHELIUM; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG DOSE REGIMEN; DRUG MECHANISM; DRUG POTENTIATION; ENZYME INHIBITION; ESOPHAGUS CARCINOMA; ESOPHAGUS MUCOSA; FATTY ACID ANALYSIS; GASTROINTESTINAL SURGERY; MALE; MASS SPECTROMETRY; NONHUMAN; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REVIEW; STATISTICAL SIGNIFICANCE;

12-HYDROXY-5,8,10,14-EICOSATETRAENOIC ACID; ANIMALS; ARACHIDONIC ACID; BODY WEIGHT; CYCLOOXYGENASE 2; DINOPROSTONE; EFLORNITHINE; ESOPHAGEAL NEOPLASMS; ESOPHAGUS; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HYDROXYEICOSATETRAENOIC ACIDS; IMMUNOENZYME TECHNIQUES; IN SITU HYBRIDIZATION; INFLAMMATION; ISOENZYMES; LEUKOTRIENE B4; MALE; MASS SPECTROMETRY; NEOPLASMS; NORDIHYDROGUAIARETIC ACID; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RATS; RATS, SPRAGUE-DAWLEY; SULINDAC; TIME FACTORS;

EID: 0036964624     PISSN: 01433334     EISSN: None     Source Type: Journal    
DOI: 10.1093/carcin/23.12.2095     Document Type: Review

References (68)

1. Blot,W.J., Devesa,S.S. and Fraumeni,J.F. (1993) Continuing climb in rates of esophageal adenocarcinoma: an update. J. Am. Med. Assoc., 270, 1320.
2. Farrow,D.C. and Vaughan,T.L. (1996) Determinants of survival following the diagnosis of esophageal adenocarcinoma (United States). Cancer Causes Control, 7, 332-327.
3. Chen,X., Yang,G.-Y, Ding,W.D., Bondoc,F., Curtis,S.K. and Yang,C.S. (1999) An esophagogastroduodenal anastomosis model for esophageal adenocarcinogenesis in rats and enhancement by iron overload. Carcinogenesis, 20, 1801-1807.
4. Chen,X. and Yang,C.S. (2001) Esophageal adenocarcinoma: a review and perspectives on the mechanism of carcinogenesis and chemoprevention. Carcinogenesis, 22, 1119-1129.
5. Thun,M.J., Namboodiri,M.M., Calle,E.E., Flanders,W.D. and Heath,C.W.J. (1993) Aspirin use and risk of fatal cancer. Cancer Res., 53, 1322-1327.
6. Farrow,D.C., Vaughan,T.L., Hansten,P.D. et al. (1998) Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol. Biomarkers Prev., 7, 97-102.
7. Hong,S.H., Avis,I., Vos,M.D., Martinez,A., Treston,A.M. and Mulshine,J.L. (1999) Relationship of arachidonic acid metabolizing enzyme expression in epithelial cancer cell lines to the growth effect of selective biochemical inhibitors. Cancer Res., 59, 2223-2228.
8. Chiu,C.H., McEntee,M.F. and Whelan,J. (2000) Discordant effect of aspirin and indomethacin on intestinal tumor burden in Apc (Min/+) mice. Prostaglandins Leukot. Essent. Fatty Acids, 62, 269-275.
9. van Rees,B.P. and Ristimaki,A. (2001) Cyclooxygenase-2 in carcinogenesis of the gastrointestinal tract. Scand. J. Gastroenterol., 36, 897-903.
10. Li,M., Lotan,R., Levin,B., Tahara,E., Lippman,S.M. and Xu,X.C. (2000) Aspirin induction of apoptosis in esophageal cancer: a potential for chemoprevention. Cancer Epidemiol. Biomarkers Prev., 9, 545-549.
11. Li,Z., Shimada,Y., Kawabe,A., Sato,F., Maeda,M., Komoto,I., Hong,T., Ding,Y., Kaganoi,J. and Imamura,M. (2001) Suppression of N-nitrosomethylbenzylamine (NMBA)-induced esophageal tumorigenesis in F344 rats by JTE-522, a selective COX-2 inhibitor. Carcinogenesis, 22, 547-551.
12. Long,J.D. and Orlando,R.C. (2000) Eicosanoids and the esophagus. Prostaglandins Other Lipid Mediat., 61, 91-104.
13. Triadafilopoulos,G., Kaczynska,M. and Iwane,M. (1996) Esophageal mucosal eicosanoids in gastroesophageal reflux disease and Barrett's esophagus. Am. J. Gastroenterol., 91, 65-74.
14. Marcinkiewicz,M., Sarosiek,J., Edmunds,M., Scheurich,J., Weiss,P. and McCallum,R.W. (1995) Monophasic luminal release of PGE2 in patients with reflux esophagitis under the impact of acid and acid/pepsin solutions. J. Clin. Gastroenterol., 21, 268-274.
15. Umansky,M., Yasui,W., Hallak,A. et al. (2001) Proton pump inhibitors reduce cell cycle abnormalities in Barrett's esophagus. Oncogene, 20, 7987-7991.
16. Wilson,K.T., Fu,S., Ramanujam,K.S. and Meltzer,S.J. (1998) Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas. Cancer Res., 58, 2929-2934.
17. Morris,C.D., Armstrong,G.R., Bigley,G., Green,H. and Attwood,S.E. (2001) Cyclooxygenase-2 expression in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence. Am. J. Gastroenterol., 96, 990-996.
18. Kandil,H.M., Tanner,G., Smalley,W., Halter,S., Radhika,A. and Dubois,R.N. (2001) Cyclooxygenase-2 expression in Barrett's esophagus. Dig. Dis. Sci., 46, 785-789.
19. Buskens, C.J., Van Rees, B.P., Sivula, A., Reitsma, J.B., Haglund, C., Bosma, P.J., Offerhaus, G.J., Van Lanschot, J.J. and Ristimaki, A. (2002) Prognostic significance of elevated cyclooxygenase 2 expression in patients with adenocarcinoma of the esophagus. Gastroenterology, 122, 1800-1807.
20. Aggarwal, S., Taneja, N., Lin, L., Orringer, M.B., Rehemtulla, A. and Beer, D.G. (2000) Indomethacin-induced apoptosis in esophageal adenocarcinoma cells involves upregulation of Bax and translocation of mitochondrial cytochrome C independent of Cox2 expression. Neoplasia, 2, 346-356.
21. Zhang, F., Subbaramaiah, K., Altorki, N. and Dannenberg, A.J. (1998) Dihydroxy bile acids activate the transcription of cyclooxygenase-2. J. Biol. Chem., 273, 2424-2428.
22. Shirvani, V.N., Ouatu-Lascar, R., Kaur, B.S., Omary, M.B. and Triadafilopoulos, G. (2000) Cyclooxygenase 2 expression in Barrett's esophagus and adenocarcinoma: ex vivo induction by bile salts and acid exposure. Gastroenterology, 118, 487-496.
23. Sarosiek, J., Yu, Z., Namiot, Z., Rourk, R.M., Hetzel, D.P. and McCallum, R.W. (1994) Impact of acid and pepsin on human esophageal prostaglandins. Am. J. Gastroenterol., 89, 588-594.
24. Souza, R.F., Shewmake, K., Beer, D.G., Cryer, B. and Spechler, S.J. (2000) Selective inhibition of cyclooxygenase-2 induces apoptosis in human esophageal adenocarcinoma cells. Cancer Res., 60, 5767-5772.
25. Buttar, N.S., Wang, K.K., Anderson, M.A., Dierkhising, R.A., Pacifico, R.J., Krishnadath, K.K. and Lutzke, L.S. (2002) The effect of selective cyclooxygenase-2 inhibition in Barrett's esophagus epithelium: an in vitro study. J. Natl Cancer Inst., 94, 422-429.
26. Steele, V.E., Holmes, C.A., Hawk, E.T., Kopelovich, L., Lubet, R.A., Crowell, J.A., Sigman, C.C. and Kelloff,G.J. (1999) Lipoxygenase inhibitors as potential cancer chemopreventives. Cancer Epidemiol. Biomarkers Prev., 8, 467-483.
27. Rioux, N. and Castonguay, A. (1998) Inhibitors of lipoxygenase: a new class of cancer chemopreventive agents. Carcinogenesis, 19, 1393-1400.
28. Shureiqi, I. and Lippman, S.M. (2001) Lipoxygenase modulation to reverse carcinogenesis. Cancer Res., 61, 6307-6312.
29. Meyskens, F.L.,Jr and Gerner, E.W. (1999) Development of difluoromethylornithine (DFMO) as a chemoprevention agent. Clin. Cancer Res., 5, 945-951.
30. Gray, M.R., Wallace, H.M., Goulding, H., Hoffman, J., Kenyon, W.E. and Kingsnorth, A.N. (1993) Mucosal polyamine metabolism in the columnar lined oesophagus. Gut, 34, 584-587.
31. Garewal, H.S., Gerner, E.W., Sampliner, R.E. and Roe, D. (1988) Ornithine decarboxylase and polyamine levels in columnar upper gastrointestinal mucosae in patients with Barrett's esophagus. Cancer Res., 48, 3288-3291.
32. Li, H., Schut, H.A., Conran, P., Kramer, P.M., Lubet, R.A., Steele, V.E., Hawk, E.E., Kelloff, G.J. and Pereira, M.A. (1999) Prevention by aspirin and its combination with alpha-difluoromethylornithine of azoxymethane-induced tumors, aberrant crypt foci and prostaglandin E2 levels in rat colon. Carcinogenesis, 20, 425-430.
33. Jacoby, R.F., Cole, C.E., Tutsch, K., Newton, M.A., Kelloff, G., Hawk, E.T. and Lubet, R.A. (2000) Chemopreventive efficacy of combined piroxicam and difluoromethylornithine treatment of Apc mutant Min mouse adenomas and selective toxicity against Apc mutant embryos. Cancer Res., 60, 1864-1870.
34. Fong, L.Y., Nguyen, V.T., Pegg, A.E. and Magee, P.N. (2001) Alpha-difluoromethylornithine induction of apoptosis: a mechanism which reverses pre-established cell proliferation and cancer initiation in esophageal carcinogenesis in zinc-deficient rats. Cancer Epidemiol. Biomarkers Prev., 10, 191-199.
35. Gerner, E.W., Garewal, H.S., Emerson, S.S. and Sampliner, R.E. (1994) Gastrointestinal tissue polyamine contents of patients with Barrett's esophagus treated with alpha-difluoromethylornithine. Cancer Epidemiol. Biomarkers Prev., 3, 325-330.
36. Kempen, E.C., Yang, P., Felix, E., Madden, T. and Newman, R.A. (2001) Simultaneous quantification of arachidonic acid metabolites in cultured tumor cells using high-performance liquid chromatography/electrospray ionization tandem mass spectrometry. Anal. Biochem., 297, 183-190.
37. Khuri, F.R., Wu, H., Lee, J.J., Kemp, B.L., Lotan, R., Lippman, S.M., Feng, L., Hong, W.K. and Xu, X.C. (2001) Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin. Cancer Res., 7, 861-867.
38. Laska, E.M., Meisner, M. and Siegel,C. (1994) Simple designs and model-free tests for synergy. Biometrics, 50, 834-841.
39. Lewin, K.J. and Appelman, H.D. (1995) Barrett's esophagus, columnar dysplasia and adenocarcinoma of the esophagus. In Lewin,K.J. and Appelman,H.D. (eds), Tumors of the Esophagus and Stomach. AFIP, Washington DC, pp. 99-144.
40. Brown,A.P., Morrissey, R.L.. Crowell, J.A. and Levine, B.S. (1999) Difluoromethylornithine in combination with tamoxifen in female rats: 13-week oral toxicity study. Cancer Chemother. Pharmacol., 44, 475-483.
41. Moody, T.W., Leyton, J., Martinez, A., Hong, S., Malkinson, A. and Mulshine, J.L. (1998) Lipoxygenase inhibitors prevent lung carcinogenesis and inhibit non-small cell lung cancer growth. Exp. Lung Res., 24, 617-628.
42. Fischer, S.M., Conti, C.J., Lubet, R.A. and Aldaz, M. (2002) Celecoxib and difluromethylornithine in combination have strong therapeutic activity against UV-induced skin tumors in mice. Proc. Am. Assoc. Cancer Res., 43, A3325.
43. Reddy, B.S., Maruyama, H. and Kelloff, G. (1987) Dose-related inhibition of colon carcinogenesis by dietary piroxicam, a nonsteroidal antiinflammatory drug, during different stages of rat colon tumor development. Cancer Res., 47, 5340-5346.
44. Grubbs, C.J., Lubet, R.A., Koki, A.T., Leahy, K.M., Masferrer, J.L., Steele, V.E., Kelloff, G.J., Hill, D.L. and Seibert, K. (2000) Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats. Cancer Res., 60, 5599-5602.
45. Buttar,N.S., Wang, K.K., Leontovich, O., Westcott, J.Y., Pacifico, R.J., Anderson, M.A., Krishnadath, K.K., Lutzke, L.S. and Burgart, L.J. (2002) Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus. Gastroenterology, 122, 1101-1112.
46. Narumiya, S., Sugimoto, Y. and Ushikubi, F. (1999) Prostanoid receptors: structures, properties and functions. Physiol. Rev., 79, 1193-1226.
47. Sheng, H., Shao, J., Washington, M.K. and DuBois,R.N. (2001) Prostaglandin E2 increases growth and motility of colorectal carcinoma cells. J. Biol. Chem., 276, 18075-18081.
48. Mutoh,M., Watanabe,K., Kitamura, T. et al. (2002) Involvement of prostaglandin E receptor subtype EP4 in colon carcinogenesis. Cancer Res., 62, 28-32.
49. δ716 knockout mice. Nat. Med., 7, 1048-1051.
50. Watanabe, K., Kawamori, T., Nakasugi, S. et al. (1999) Role of the prostaglandin E receptor subtype EP1 in colon carcinogenesis. Cancer Res., 59, 5093-5096.
51. Agarwal, R., Wang, Z.Y., Bik, D.P. and Mukhtar,H. (1991) Nordihydroguaiaretic acid, an inhibitor of lipoxygenase, also inhibits cytochrome P-450-mediated monooxygenase activity in rat epidermal and hepatic microsomes. Drug Metab. Dispos., 19, 620-624.
52. Ding, X.Z., Iversen, P., Cluck, M.W., Knezetic, J.A. and Adrian, T.E. (1999) Lipoxygenase inhibitors abolish proliferation of human pancreatic cancer cells. Biochem. Biophys. Res. Commun., 261, 218-223.
53. Seufferlein, T., Seckl, M.J., Schwarz, E., Beil, M., v Wichert, G., Baust, H., Luhrs,H., Schmid, R.M. and Adler, G. (2002) Mechanisms of nordihydroguaiaretic acid-induced growth inhibition and apoptosis in human cancer cells. Br. J. Cancer, 86, 1188-1196.
54. Noguchi, M., Rose, D.P., Earashi, M. and Miyazaki,I. (1995) The role of fatty acids and eicosanoid synthesis inhibitors in breast carcinoma. Oncology, 52, 265-271.
55. Nakadate, T. (1989) The mechanism of skin tumor promotion caused by phorbol esters: possible involvement of arachidonic acid cascade/lipoxygenase, protein kinase C and calcium/calmodulin systems. Jpn. J. Pharmacol., 49, 1-9.
56. Pachernik, J., Hampl, A., Soucek, K., Kovarikova, M., Andrysik, Z., Hofmanova, J. and Kozubik,A. (2002) Multiple biological effects of inhibitors of arachidonic acid metabolism on human keratinocytes. Arch. Dermatol. Res., 293, 626-633.
57. Ansar, S., Iqbal, M. and Athar, M. (1999) Nordihydroguairetic acid is a potent inhibitor of ferric-nitrilotriacetate-mediated hepatic and renal toxicity and renal tumour promotion in mice. Carcinogenesis, 20, 599-606.
58. Petrich, K., Ludwig, P., Kuhn, H. and Schewe, T. (1996) The suppression of 5-lipoxygenation of arachidonic acid in human polymorphonuclear leucocytes by the 15-lipoxygenase product (15S)-hydroxy-(5Z,8Z,11Z,13E)-eicosatetraenoic acid: structure-activity relationship and mechanism of action. Biochem. J., 314, 911-916.
59. Brenner, D.E., Normolle, D.P., Kresty, L.A. et al. (2002) Effect of difluoromethylornithine (DFMO) upon cellular proliferation and cyclin D expression in human metaplastic Barrett's esophagus mucosa. Proc. Am. Assoc. Cancer Res., 43, A4989.
60. Brenner, D.E., Normolle, D.P., Kresty, L.A. et al. (2002) Effect of difluoromethylornithine (DFMO) upon polyamine content in human metaplastic Barrett's Esophagus mucosa. Proc. Am. Assoc. Cancer Res., 43, A5679.
61. Hardy, A. and Catros-Quemener,V. (1998) Neomycin inhibition of intestinal putrescine uptake. Anticancer Res., 18, 4163-4169.
62. Okamoto, A., Sugi, E., Koizumi, Y., Yanagida, F. and Udaka,S. (1997) Polyamine content of ordinary foodstuffs and various fermented foods. Biosci. Biotechnol. Biochem., 61, 1582-1584.
63. Benamouzig, R., Mahe, S., Luengo, C., Rautureau, J. and Tome, D. (1997) Fasting and postprandial polyamine concentrations in the human digestive lumen. Am. J. Clin. Nutr., 65, 766-770.
64. Osborne, D.L. and Seidel, E.R. (1990) Gastrointestinal luminal polyamines: cellular accumulation and enterohepatic circulation. Am. J. Physiol., 258, G576-584.
65. Avis, I., Hong, S.H., Martinez, A., Moody, T., Choi, Y.H., Trepel, J., Das, R., Jett, M. and Mulshine, J.L. (2001) Five-lipoxygenase inhibitors can mediate apoptosis in human breast cancer cell lines through complex eicosanoid interactions. FASEB J., 15, 2007-2009.
66. Frommel, T.O., Dyavanapalli, M., Oldham, T., Kazi, N., Lietz, H., Liao, Y. and Mobarhan, S. (1997) Effect of aspirin on prostaglandin E2 and leukotriene B4 production in human colonic mucosa from cancer patients. Clin. Cancer Res., 3, 209-213.
67. Ondrey, F.G., Juhn, S.K. and Adams, G.L. (1996) Inhibition of head and neck tumor cell growth with arachidonic acid metabolism inhibition. Laryngoscope, 106, 129-134.
68. Avis, I.M., Jett, M., Boyle, T., Vos, M.D., Moody, T., Treston, A.M., Martinez, A. and Mulshine, J.L. (1996) Growth control of lung cancer by interruption of 5-lipoxygenase-mediated growth factor signaling. J. Clin. Invest., 97, 806-813